Raymond James upgraded InflaRx (IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Following Q1 earnings, sentiment is increasingly supported by a constructive view on InflaRx’s izicopan program in AAV, backed by a recent $150M financing that extends runway into proof-of-concept development, with preclinical and early clinical signals suggesting potentially improved potency, reduced hepatotoxicity risk, and simpler dosing versus avacopan, while also positioning the program to benefit from validated C5aR biology and broader complement-related opportunities across renal indications, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx price target raised to $8 from $6 at H.C. Wainwright
- InflaRx Raises $150 Million in Underwritten Share Offering Filed in Early May 2026
- InflaRx to develop izicopan in AAV
- InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029
- InflaRx Files Q1 2026 Financials with SEC via Form 6-K